| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Eyenovia, Inc. (NASDAQ:EYEN), a commercial-stage ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive myopia, and SGN Nanopharma, today announced that the companies have entered into a collaboration agreement to develop a treatment for chronic dry eye disease.
Under the terms of the agreement, the companies will work to develop SGN's Micellar Nanoparticle Platform (MNP) platform-based cyclosporine formulation for use with Eyenovia's Optejet® dispenser. The companies are currently validating the novel drug-device combination product's manufacturability to support clinical testing and will then schedule a consultation meeting with the FDA to discuss clinical development.
Posted In: EYEN
